On September 11, 2023, Seth Van Voorhees, Ph.D., resigned from his position as the Chief Financial Officer of the NRx Pharmaceuticals, Inc. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition. Mr. Van Voorhees?s resignation was not the result of any disagreement regarding any matter relating to the Company?s operations, policies, or practices. On September 14, 2023, the Company announced the appointment of Mr. Narido as the Company?s Interim Chief Financial Officer, the entry into LifeSci Agreement and Mr. Van Voorhees?s resignation as the Company?s Chief Financial Officer.

Mr. Narido most recently served as the Chief Financial Officer of Lucira Health (?Lucira?) until Pfizer Inc.?s acquisition of Lucira in April 2023. From July 2018 to March 2021, Mr. Narido served in various roles at Assembly Biosciences, Inc., including most recently as Executive Director, Finance, Controllership and Treasury. From June 2014 to June 2018, Mr. Narido served in various roles at Bio-Rad Laboratories, Inc., including as Americas Head of Finance, Global Commercial Operations.

Prior to June 2018, Mr. Narido held various finance roles, including Global Head Finance Reporting and Accounting for Novartis Vaccines and Diagnostics Division and several industry-related positions, including Business Unit Controller for McKesson Corporation. Mr. Narido also serves as a board member on the Arthritis National Research Foundation?s board of directors. Mr. Narido started his career with PricewaterhouseCoopers?s Financial Audit and Assurance practice.

Mr. Narido holds a Bachelor of Science degree from the University of San Francisco and a Master of Science degree from the Pepperdine Graziadio Business School.